A study links sensory-neuron clock state to sodium-channel function. Synchronized human iPSC-derived nociceptors showed clock-state-dependent changes in excitability, and cryptochrome stabilization reduced hyperexcitability.
The study asked how clock state produces time-of-day changes in nociception and whether this axis can be targeted for analgesia. Researchers at Oxford and Kent combined circadian behavioral analyses, sensory-neuron genetics, electrophysiology and pharmacological modulation to investigate pain rhythmicity. Loss of cryptochromes CRY1/CRY2 disrupted time-of-day differences in nociceptor excitability. The study linked cryptochrome state to voltage-gated sodium-channel function.
A small-molecule cryptochrome stabilizer suppressed sodium currents and nociceptive responses across the tested paradigms. The effect was lost when cryptochrome function was absent, supporting dependence on this clock component.
The translational experiments used human induced pluripotent stem cell (iPSC)-derived nociceptors, including a human pain-disease model. After synchronization, the cells showed concordant clock-state-dependent changes in excitability. Cryptochrome stabilization reduced hyperexcitability in these human models.
These human experiments tested clock-state-dependent neuronal excitability and its pharmacological modulation. Together with the genetic and behavioral findings, they support cryptochromes as effectors linking circadian state to nociceptor function and motivate evaluation of this non-opioid target.
A four-platform comparison combined lipid imaging, liver-function measurements, expression profiling and CYP assays. Lipid accumulation did not uniformly reduce drug metabolism, and differences depended on the model and donor.
A 512-compound screen in patient-derived motor neurons identified resveratrol tetramers with neuroprotective activity. Follow-up work covered 14 iPSC lines and linked protection to changes in neuronal excitability.
